Related Experiment Video

Updated: Jul 18, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease

P Holvoet1, G Perez, Z Zhao

  • 1Center for Molecular and Vascular Biology, University of Leuven, Belgium.

The Journal of Clinical Investigation
|June 1, 1995
PubMed

Insights

Elevated levels of malondialdehyde-modified LDL (MDA-LDL) in plasma are linked to unstable atherosclerotic cardiovascular disease. This finding suggests MDA-LDL may serve as a valuable biomarker for disease progression.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Biochemistry

Background:

  • Atherosclerosis involves the modification of low-density lipoprotein (LDL).
  • Malondialdehyde (MDA)-modified LDL is a specific form of modified LDL implicated in atherogenesis.
  • Detecting MDA-modified LDL could aid in assessing cardiovascular disease risk.

Purpose of the Study:

  • To investigate the presence and levels of MDA-modified LDL in human plasma.
  • To evaluate MDA-modified LDL as a potential biomarker for atherosclerotic cardiovascular disease.

Main Methods:

  • Development and use of a murine monoclonal antibody (mAb-1H11) against MDA-modified LDL.
  • Quantification of plasma MDA-modified LDL levels in control subjects and patients with cardiovascular conditions.
  • Characterization of isolated modified LDL properties (electrophoretic mobility, thiobarbituric acid reactive substances, cholesterol/protein ratio).
  • Assessment of modified LDL uptake by macrophages and foam cell formation.

Main Results:

  • Plasma MDA-modified LDL levels were significantly elevated in patients with acute myocardial infarction (1.4 mg/dl) and carotid atherosclerosis (0.86 mg/dl) compared to controls (0.19 mg/dl).
  • Levels were not significantly different in patients with chronic stable angina.
  • Isolated modified LDL exhibited altered biochemical properties and induced foam cell generation in macrophages.
  • The apo B-100 moiety of modified LDL remained intact.

Conclusions:

  • Elevated plasma levels of atherogenic MDA-modified LDL are associated with acute myocardial infarction and carotid atherosclerosis.
  • MDA-modified LDL may serve as a biomarker for unstable atherosclerotic cardiovascular disease.
  • Further research is warranted to explore its clinical utility.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Inflammation01:38

Inflammation

Overview
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...